Welcome back to the new and improved Endpoints Weekly! This week we’ll be recapping the JP Morgan Healthcare Conference, IRA ...

Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze ...

Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger ...

CMS didn't wait for President-elect Donald Trump to take office before issuing its second list of drugs to be negotiated ...

WuXi AppTec sells US device testing sites to NAMSA, Notch Therapeutics cuts staff, and Neurizon's ALS drug NUZ-001 faces FDA clinical hold.

Novo Nordisk's high-dose Wegovy shows 20.7% weight loss in Phase 3 but falls short of Eli Lilly's Zepbound, raising questions ...

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...

FDA approves AstraZeneca's Calquence as first BTK inhibitor for first-line mantle cell lymphoma, leading BeiGene's Brukinsa ...

FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...

Novartis is the latest drugmaker to sue the government for allegedly rejecting its proposed model to distribute federal drug ...